C-terminal Octylation Rescues an Inactive T20 Mutant

T20, a synthetic peptide corresponding to a C-terminal segment of the envelope glycoprotein (gp41) of human and simian immunodeficiency viruses, is a potent inhibitor of viral infection. We report here that C-terminal octylation of simian immunodeficiency virus gp41-derived T20 induces a significant increase in its inhibitory potency. Furthermore, when C-terminally octylated, an otherwise inactive mutant in which the C-terminal residues GNWF were replaced by ANAA has potency similar to that of the wild type T20. This effect cannot be explained by a trivial inhibitory effect of the octyl group added to the peptides, because the N-terminally octylated peptides have the same activity as the non-octylated parent peptides. The effects caused by octylation on the oligomerization, secondary structure, and membrane-interaction properties of the peptides were investigated. Our results shed light on the mechanism of inhibition by T20 and provide experimental support for the existence of a pre-hairpin intermediate.

[1]  Y. G. Yu,et al.  Two interaction modes of the gp41-derived peptides with gp41 and their correlation with antimembrane fusion activity. , 1999, Biochemical and biophysical research communications.

[2]  J. Griffin,et al.  Protein synthesis by native chemical ligation: expanded scope by using straightforward methodology. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S. Durell,et al.  Dilation of the Human Immunodeficiency Virus–1 Envelope Glycoprotein Fusion Pore Revealed by the Inhibitory Action of a Synthetic Peptide from gp41 , 1998, The Journal of cell biology.

[4]  Y. Shai,et al.  Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation. , 2000, Journal of molecular biology.

[5]  Y. Shai,et al.  Channel formation properties of synthetic pardaxin and analogues. , 1990, The Journal of biological chemistry.

[6]  Eric Hunter,et al.  Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry , 1998, Nature Medicine.

[7]  A. Agirre,et al.  Membrane Interface-Interacting Sequences within the Ectodomain of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein: Putative Role during Viral Fusion , 2000, Journal of Virology.

[8]  B. Fehse,et al.  Membrane-Anchored Peptide Inhibits Human Immunodeficiency Virus Entry , 2001, Journal of Virology.

[9]  M. Matsuoka,et al.  Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. , 2002, Angewandte Chemie.

[10]  J. Sodroski,et al.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. , 1987, Science.

[11]  A. Gronenborn,et al.  Three‐dimensional solution structure of the 44 kDa ectodomain of SIV gp41 , 1998, The EMBO journal.

[12]  R. Blumenthal,et al.  Role of the Membrane-Proximal Domain in the Initial Stages of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein-Mediated Membrane Fusion , 1999, Journal of Virology.

[13]  W. Gallaher,et al.  Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus , 1987, Cell.

[14]  R. B. Merrifield,et al.  Synthesis of the antibacterial peptide cecropin A (1-33). , 1982, Biochemistry.

[15]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[16]  C. Weiss,et al.  Capture of an early fusion-active conformation of HIV-1 gp41 , 1998, Nature Structural Biology.

[17]  C. Broder,et al.  CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.

[18]  Samuel K Sia,et al.  Short constrained peptides that inhibit HIV-1 entry , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Y. G. Yu,et al.  Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1. , 2000, AIDS research and human retroviruses.

[20]  T. Matthews,et al.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Skehel,et al.  Coiled Coils in Both Intracellular Vesicle and Viral Membrane Fusion , 1998, Cell.

[22]  Y. Shai,et al.  Conjugation of a magainin analogue with lipophilic acids controls hydrophobicity, solution assembly, and cell selectivity. , 2002, Biochemistry.

[23]  C. Toniolo,et al.  Structural features and conformational equilibria of 310-helical peptides in solution by spectroscopic and molecular mechanics studies. , 2002, Biopolymers.

[24]  T. Copeland,et al.  Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. , 1985, Science.

[25]  M. Greaves,et al.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus , 1984, Nature.

[26]  K. Guthrie,et al.  HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. , 1996, Biochemistry.

[27]  Y. Hayek,et al.  A monomeric 3(10)-helix is formed in water by a 13-residue peptide representing the neutralizing determinant of HIV-1 on gp41. , 2002, Biochemistry.

[28]  F. Goñi,et al.  Interbilayer lipid mixing induced by the human immunodeficiency virus type-1 fusion peptide on large unilamellar vesicles: the nature of the nonlamellar intermediates. , 1999, Chemistry and physics of lipids.

[29]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[30]  Christos,et al.  Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  C. Toniolo,et al.  Factors governing 310-Helix vs α-helix formation in peptides: Percentage of cα-tetrasubstituted α-amino acid residues and sequence dependence , 2002 .

[32]  Paul E. Kennedy,et al.  HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.

[33]  S. A. Gallo,et al.  Mode of Action of an Antiviral Peptide from HIV-1 , 2001, The Journal of Biological Chemistry.

[34]  C. Toniolo,et al.  The first water-soluble 3(10)-helical peptides. , 2000, Chemistry.

[35]  P S Kim,et al.  Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[36]  P. S. Kim,et al.  A spring-loaded mechanism for the conformational change of influenza hemagglutinin , 1993, Cell.

[37]  G. Clore,et al.  Monomer‐trimer equilibrium of the ectodomain of SIV gp41: Insight into the mechanism of peptide inhibition of HIV infection , 1999, Protein science : a publication of the Protein Society.

[38]  C. Toniolo,et al.  Solution Structure, Dimerization, and Dynamics of a Lipophilic α/310-Helical, Cα-Methylated Peptide. Implications for Folding of Membrane Proteins , 2001 .

[39]  G. Semenza,et al.  Hydrophobic binding of the ectodomain of influenza hemagglutinin to membranes occurs through the "fusion peptide". , 1989, The Journal of biological chemistry.